Attovia Therapeutics Raises $90M in Series C Financing

Attovia Therapeutics, a San Carlos, CA-based clinical-stage biopharma company, raised $90M in Series C funding.

The round was led by Deep Track Capital with participation from new investors including Vida Ventures, Sanofi Ventures, and Mirae Asset Capital Life Science, and ongoing support from existing investors including Frazier Life Sciences, venBio, Goldman Sachs Alternatives, Nextech Ventures, Cormorant Asset Management, EcoR1 Capital, Marshall Wace, and Illumina Ventures.

In conjunction with the financing, Rebecca Luse, Managing Director at Deep Track Capital, will join the Company’s Board of Directors.

The company intends to use the funds to advance its lead assets, ATTO-1310 and ATTO-3712.

Founded by CEO Tao Fu, Attovia is a clinical-stage biopharma company developing treatments for immune-mediated diseases creating a pipeline of biotherapeutics for the treatment of immune-mediated diseases. It leverages ATTOBODY, its proprietary biologics platform that utilize spatial positioning technology to achieve biparatopic target engagement.

Its first ATTOBODY-based product candidate, ATTO-1310, is a first-in-class, half-life extended anti-IL31 biologic, currently in Phase 1 studies, to provide a highly efficacious, fast acting, and convenient treatment option for chronic pruritus of unknown origin (CPUO)—a disease affecting millions of patients in the U.S. and other developed countries with currently no approved treatments—as well as additional pruritic conditions with urgent unmet need.

Attovia is also advancing ATTO-3712, a first-in-class anti-IL13 x IL31, half-life extended bispecific designed to provide breakthrough efficacy and convenient dosing in atopic dermatitis and potentially chronic spontaneous urticaria, prurigo nodularis, and other inflammatory skin conditions. The company plans to start Phase 1 clinical studies with ATTO-3712 in the second half of 2025.

Attovia’s earlier-stage pipeline includes ATTO-004, a multi-specific drug candidate targeting IBD, and two other multi-specific discovery-stage programs.

FinSMEs

16/04/2025